Noninfectious endophthalmitis associated with intravitreal triamcinolone injection

Archives of Ophthalmology

Volumn 121, Issue 9, 2003, Pages 1279-1282

  Roth, Daniel B ^a   Chieh, Janet ^a   Spirn, Marc J ^a   Green, Stuart N ^a   Yarian, David L ^a   Chaudhry, Nauman A ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b New England Retina Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PREDNISOLONE; TRIAMCINOLONE; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ANTERIOR EYE CHAMBER DISEASE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CULTURE MEDIUM; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ADMINISTRATION ROUTE; ENDOPHTHALMITIS; EXUDATE; EYE INFLAMMATION; FEMALE; HAND MOVEMENT; HUMAN; HYPOPYON; INJECTION; MALE; PATIENT; PRIORITY JOURNAL; PSEUDOPHAKIA; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; SIMULATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY; VITREOUS DISEASE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; PSEUDOPHAKIA; RETINAL VEIN OCCLUSION; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 0141499061     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.9.1279     Document Type: Article

References (26)

1. Ting TD, Oh M, Cox TA, Meyer CH, Toth CA. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol. 2002;120:731-737.
2. Freeman G, Matos K, Pavesio CE. Cystoid macular oedema in uveitis: an unsolved problem. Eye. 2001;15:12-17.
3. Smith SC. Nonproliferative diabetic retinopathy and macular edema. Insight. 1999;24:59-62.
4. Harbour JW, Smiddy WE, Rubsamen PE, et al. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. Am J Ophthalmol. 1995;120:302-307.
5. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107:2034-2038.
6. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98:766-785.
7. Clarkson JG. Photocoagulation for ischemic central retinal vein occlusion: Central Vein Occlusion Study. Arch Ophthalmol. 1991;109:1218-1219.
8. Ito Y, Terasaki H, Mori M, et al. Three-dimensional optical coherence tomography of vitreomacular traction syndrome before and after vitrectomy. Retina, 2000;20:403-405.
9. Hood PP, Cotter TP, Costello JF, Sampson AP. Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients. Thorax. 1999;54:1075-1082.
10. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110:1155-1159.
11. Osaki NK, Behany KD, Nishihara KC, et al. Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia. Invest Ophthalmol Vis Sci. 2002;43:1546-1557.
12. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-77.
13. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91:785-788.
14. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29:2-6.
15. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol. 2002;86:247-248.
16. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol. 2001;119:1380-1383.
17. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765-772.
18. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
19. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26:277-281.
20. Penfold PL, Wen L, Madigan MO, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000;121:458-465.
21. Penfold PL. Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br J Ophthalmol. 2002;86:600-601.
22. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol. 2002;86:527-529.
23. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 1999;27:431-432.
24. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2002;240:42-48.
25. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001;29:188-192.
26. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;119:399-404.